RSNA 2011 

Abstract Archives of the RSNA, 2011


SSA15-05

fMRI in Resting State as a Radiological Tool in Pharmaceutic Research: An Experimental Clinical Trial with Alprazolam

Scientific Formal (Paper) Presentations

Presented on November 27, 2011
Presented as part of SSA15: Neuroradiology (Advanced Imaging)

Participants

Marco Barillari MD, Presenter: Nothing to Disclose
Roberto Cerini MD, Abstract Co-Author: Nothing to Disclose
Carlo Cacciatori, Abstract Co-Author: Nothing to Disclose
Federica Spagnolli, Abstract Co-Author: Nothing to Disclose
Nicolò Cardobi, Abstract Co-Author: Nothing to Disclose
Roberto Pozzi Mucelli, Abstract Co-Author: Nothing to Disclose
Riccardo Manfredi MD, Abstract Co-Author: Nothing to Disclose
Cristina Costantin, Abstract Co-Author: Nothing to Disclose
Valentina Lotto, Abstract Co-Author: Nothing to Disclose
Stefano Milleri, Abstract Co-Author: Nothing to Disclose

PURPOSE

The aim of the study was to highlight the presence of modifications in the Default Mode Network (DMN) detected by means of fMRI in Resting State after the administration of a neurotropic drug, the Alprazolam, and therefore to suggest fMRI as an alternative and non invasive tool for future pharmacological experimentations in vivo.

METHOD AND MATERIALS

11 healthy subjects (5 males; mean age: 32 years) were enrolled in a double-blind randomized study. They received Alprazolam or placebo and underwent two fMRI scans each. Data were acquired at 1.5 T (Magnetom Symphony, Siemens, Enlargen, Germany). Functional connectivity and activation maps were obtained by means of independent component analysis using FSL (FMRIB software Library 4.1, Oxford, UK). A F-test (p<0.05) was applied in order to detect statistical differences between groups and Dual-Regression (p<0.05) permitted to obtain spatial maps defining the between-subject group-consistency.

RESULTS

The reproducibility of fMRI in Resting State was demonstrated with a consistent detection of DMN in all subjects and all conditions, furthermore a statistically non-significant difference between baselines was found (p<0,11242). The Dual-Regression analysis showed a diffuse significant higher functional connectivity in the brain after the administration of Alprazolam, mainly in the precuneus/posterior cingulate cortex within the DMN, and also between the DMN and other cerebral areas, in particular the basal ganglia. No significant differences in DMN were detected after placebo administration.

CONCLUSION

fMRI in Resting State reproducibility was demonstrated and connectivity modifications in DMN and other cerebral areas occur after Alprazolam administration.

CLINICAL RELEVANCE/APPLICATION

fMRI should be considered an applicable model in humans during future clinical trials.

Cite This Abstract

Barillari, M, Cerini, R, Cacciatori, C, Spagnolli, F, Cardobi, N, Pozzi Mucelli, R, Manfredi, R, Costantin, C, Lotto, V, Milleri, S, fMRI in Resting State as a Radiological Tool in Pharmaceutic Research: An Experimental Clinical Trial with Alprazolam.  Radiological Society of North America 2011 Scientific Assembly and Annual Meeting, November 26 - December 2, 2011 ,Chicago IL. http://archive.rsna.org/2011/11014638.html